| Literature DB >> 23893035 |
Daiva Gorczyca1, Jacek Postępski, Edyta Olesińska, Małgorzata Lubieniecka, Iwona Lachór-Motyka, Violetta Opoka-Winiarska, Anna Gruenpeter.
Abstract
Kawasaki disease (KD) is one of the most common vasculitides of childhood. The aim of this retrospective study is to determine the incidence of KD and to evaluate its presenting symptoms, clinical course, laboratory tests, and treatment in patients with complete KD and incomplete KD at three pediatric rheumatology centers in Poland from January 2011 to December 2012. A total of 27 Caucasian children (12 boys and 15 girls) with median age of 3 years (range 4 months-12 years) were included in this study. The incidence of complete versus incomplete KD was 17 (63 %) versus 10 (37 %) children, respectively. Patients with incomplete KD significantly less presented cervical lymphadenopathy (20 vs. 88.2 %; p = 0.00075), changes in extremities (30 vs. 76.5 %; p = 0.04), and bilateral nonpurulent conjunctivitis (60 vs. 100 %; p = 0.01). Cardiac assessments show that the majority of patients with KD have not got coronary artery aneurysms (CAA). The median time from the onset of symptoms to intravenous immunoglobulin (IVIG) infusion was 7 days for complete KD and 11 days for incomplete KD. IVIG delay in the incomplete KD had no effect on the incidence of CAA. In conclusion, there were no differences in demographic features, age of onset, and laboratory tests of patients with complete and incomplete KD. Patients with incomplete KD significantly rarely presented cervical lymphadenopathy, changes in extremities, and conjunctival injection. Electrocardiography is a sensitive test to recognize cardiac involvement in the acute phase of KD. Despite the fact that incomplete forms of presentation often delay diagnosis, in most patients treatment with IVIG can avoid complication of CAA.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23893035 PMCID: PMC4028538 DOI: 10.1007/s00296-013-2836-7
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 2.631
Demographic characteristic of the patients with Kawasaki disease
| Parameter | Whole group | Complete | Incomplete |
|
|---|---|---|---|---|
| Gender | ||||
| Male | 12 (44.4) | 6 (35.3) | 6 (60.0) | NS |
| Female | 15 (66.6) | 11 (64.7) | 4 (40.0) | |
| Age at diagnosis (months) | ||||
| <1 | 4 (14.8) | 3 (17.6) | 1 (10.0) | NS |
| 1–9 | 21 (77.8) | 12 (70.6) | 9 (90.0) | |
| >9 years | 2 (7.4) | 2 (11.8) | – | |
| Weight, percentile | ||||
| <25 | 10 (37.0) | 5 (29.4) | 5 (50.0) | NS |
| 25–75 | 9 (33.3) | 6 (35.3) | 3 (30.0) | |
| >75 | 6 (22.2) | 6 (35.3) | – | |
| Seasonal onset | ||||
| Winter | 5 (18.5) | 3 (17.6) | 2 (20.0) | NS |
| Springs | 7 (25.9) | 5 (29.4) | 2 (20.0) | |
| Summer | 8 (29.6) | 4 (23.5) | 4 (40.0) | |
| Autumn | 4 (14.8) | 2 (11.8) | 2 (20.0) | |
NS nonsignificant
Classical and “nonclassical” symptoms in complete and incomplete KD
| Whole group | Complete | Incomplete |
| |
|---|---|---|---|---|
| Classic KD clinical symptoms | ||||
| Fever persisting at least 5 days | 25 (92.6) | 15 (88.2) | 10 (100) | – |
| Bilateral conjunctival injection without exudates | 23 (85.2) | 17 (100) | 6 (60.0) | 0.012 |
| Cervical lymphadenopathy (>1.5 cm diameter) | 17 (62.9) | 15 (88.2) | 2 (20.0) | 0.00075 |
| Changes in lips and oral cavity | 26 (96.3) | 17 (100) | 9 (90.0) | NS |
| Polymorphous exanthema | 26 (96.3) | 17 (100) | 9 (90.0) | NS |
| Changes in extremities | 16 (59.3) | 13 (76.5) | 3 (30.0) | 0.040 |
| 2/3 classic KD clinical signs | – | – | 2/8 | |
| “Nonclassical” clinical symptoms | ||||
| Arthralgia, arthritis | 12 (44.4) | 8 (47.1) | 4 (40.0) | NS |
| Gastrointestinal symptoms (diarrhea, vomiting, abdominal pain) | 18 (66.7) | 10 (58.8) | 8 (80.0) | NS |
| Hepatic dysfunction | 15 (55.6) | 11 (64.7) | 4 (40.0) | NS |
| Respiratory symptoms (cough) | 4 (14.8) | 4 (23.5) | – | NS |
| Sterile pyuria | 8 (29.6) | 6 (35.3) | 2 (20.0) | NS |
KD Kawasaki disease, NS nonsignificant
Laboratory investigations and cardiovascular findings at diagnosis in complete and incomplete KD
| Whole group | Complete | Incomplete |
| |
|---|---|---|---|---|
| Median (range) | Median (range) | Median (range) | ||
| Laboratory investigations | ||||
| CRP (mg/l) | 22.4 (3.7–225.6) | 17.8 (3.7–179.9) | 31.0 (5.8–225.6) | NS |
| CRP ≥ 3 + ( | 27 (100) | 17 (100) | 10 (100) | – |
| ESR (mm/h) | 81.0 (15.0–130.0) | 80.0 (28.0–112.0) | 90.0 (15.0–.0) | NS |
| ESR ≥40 mm/h | 23 (85.2 %) | 15 (88.2 %) | 8 (80.0 %) | NS |
| Red blood cells (×1012/l) | 4.20 (3.05–4.5) | 4.06 (3.05–4.54) | 4.29 (3.17–4.75) | NS |
| Hematocrit (%) | 32.2 (25.9–38.7) | 31.2 (25.9–38.7) | 35.7 (27.9–37.5) | NS |
| Hemoglobin (g/l) | 11.2 (8.6–12.9) | 10.9 (8.6–12.4) | 11.9 (9.1–12.9) | NS |
| Anemia for age ( | 11 (40.7 %) | 7 (41.2 %) | 4 (40.0 %) | NS |
| White blood cells (× 109/l) | 14.6 (6.1–30.4) | 14.6 (6.1–30.4) | 14.9 (10.7–23.8) | NS |
| WBC count ≥15 × 109/l ( | 13 (48.1 | 8 (47.1 %) | 5 (50.0 %) | NS |
| Neutrophils (×109/l) | 12.0 (0.3–26.7) | 12.4 (0.3–26.7) | 8.6 (4.9–14.9) | NS |
| Platelets count (×109/l) | 643.0 (229.0–1121.0) | 630.0 (229.0–1121.0) | 689.5 (411.0–974.0) | NS |
| Platelets after 7 days ≥450 × 109/l ( | 24 (88.8 %) | 15 (88.2 %) | 9 (90.0 %) | NS |
| Albumin (g/l) | 3.27 (2.20–39.0) | 3.27 (3.0–3.7) | 3.41 (2.2–39.0) | NS |
| Albumin ≤3.0 g/dl ( | 22 (81.5 %) | 17 (100 %) | 5 (50.0 %) | NS |
| ALT (U/l) | 30.0 (10.0–146.0) | 28.5 (16.0–146.0) | 45.0 (10.0–.0) | NS |
| Elevated ALT ( | 12 (44.45) | 7 (43.8 %) | 5 (50.0 %) | NS |
| AST (U/l) | 44.0 (17.0–117.0) | 42.0 (17.0–111.0) | 49.0 (17.0–117.0) | NS |
| Elevated AST ( | 13 (48.1 %) | 8 (47.1 %) | 5 (50.0 %) | NS |
| Cardiovascular findings | ||||
| Coronary artery abnormalities | ||||
| | 15 (55.6 %) | 12 (70.6 %) | 6 (60.0 %) | NS |
| | 7 (25.9 %) | 4 (23.5 %) | 3 (30.0 %) | |
| | 2 (7.4 %) | 1 (5.9 %) | 1 (10.0 %) | |
| Repolarization disorders | 11 (64.7 %) | 5 (29.4 %) | 6 (60.0 %) | NS |
| Congestive heart failure, myocarditis, pericarditis, valvular regurgitation | 4 (14.8 %) | 4 (23.5 %) | – | NS |
KD Kawasaki disease, NS nonsignificant
Clinical history in complete and incomplete KD
| Whole group, | Complete, | Incomplete, |
| |
|---|---|---|---|---|
| Median (range) | Median (range) | Median (range) | ||
| Interval symptoms onset diagnosis, days | 8.5 (5–14) | 7.5 (5–13) | 11 (5–14) | NS |
| Length of hospitalization, days | 16.5 (7–45) | 17 (7–45) | 14 (9–24) | NS |
| Treated <10 days after symptoms onset, | 16 (59.2 %) | 13 (76.5 %) | 3 (30 %) | 0.026a |
KD Kawasaki disease, NS nonsignificant
aFisher’s exact test